EvlaBio closed a €21 million seed funding to complete preclinical development of a monoclonal antibody for the treatment of left ventricular hypertrophy in the setting of chronic kidney disease. The Swiss German life science company is focused on developing first-in-class therapeutics for cardiovascular and cardiorenal diseases..

EvlaBio完成了2100万欧元的种子轮融资，用于完成一种单克隆抗体的临床前开发，该抗体用于治疗慢性肾病背景下的左心室肥厚。这家瑞士德国生命科学公司专注于开发针对心血管和心肾疾病的首创疗法。

Founded with a mission to address high unmet medical need in the cardiorenal field, Swiss German biotech company

成立于瑞士德国的生物技术公司，致力于解决心血管肾脏领域未被满足的高医疗需求

EvlaBio

埃夫拉生物

is developing a targeted treatment for patients suffering from Chronic Kidney Disease (CKD) with limited therapeutic options. The company’s lead asset is a novel monoclonal antibody designed to inhibit the pathological FGF23/ FGFR4 cardiac signaling axis — a critical driver of cardiac remodeling in patients with CKD..

正在为治疗选择有限的慢性肾病 (CKD) 患者开发一种靶向治疗方法。该公司的主要资产是一种新型单克隆抗体，旨在抑制病理性 FGF23/FGFR4 心脏信号轴——这是 CKD 患者心脏重构的关键驱动因素。

“Despite recent advances, the clinical need in Left Ventricular Hypertrophy in the context of CKD remains significant, with high prevalence and substantial negative impact on patients’ outcomes. Even with improved management of hypertension and anemia, LVH often persists or even progresses in CKD patients”, said Wenzel von der Heydte, CEO & Co- Founder of EvlaBio.

“尽管最近取得了一些进展，但在慢性肾病背景下，左心室肥厚的临床需求仍然显著，其高发病率对患者的预后产生了严重的负面影响。即使在高血压和贫血的管理有所改善的情况下，左心室肥厚在慢性肾病患者中常常持续存在甚至进一步恶化，”EvlaBio首席执行官兼联合创始人温泽尔·冯·德·海特表示。

“EvlaBio’s approach is unique in its ability to directly target a key pathway on the cardiomyocyte level. This new therapeutic avenue has the potential to improve lives of millions of patients.”.

“EvlaBio的方法在其能够直接针对心肌细胞水平上的关键通路方面是独一无二的。这一新的治疗途径有潜力改善数百万患者的生活。”

The program originates from Lead Discovery Center GmbH (

该程序源自Lead Discovery Center GmbH (

LDC

长期照护（Long-term care）

), a company established in 2008 by the technology transfer organization Max Planck Innovation, where it has been developed in collaboration with

），该公司于2008年由技术转移机构马克斯·普朗克创新公司成立，并与之合作开发。

KHAN

可汗

Technology Transfer Fund I GmbH & Co KG (KHAN-I). EvlaBio is headquartered in Switzerland where also CEO Wenzel von der Heydte is based.

技术转让基金I有限公司（KHAN-I）。EvlaBio总部位于瑞士，首席执行官温泽尔·冯·德·海特也驻扎在瑞士。

“Blocking cardiac FGF23/FGFR4 overdrive has the strong potential to become a very promising treatment option for millions of patients facing a high risk of cardiac remodeling and progression to heart failure in CKD,” said Thomas Kirmeier, COO & Co- Founder of EvlaBio. “Heart failure is a leading cause of morbidity and mortality in this patient population and our therapeutic approach offers a promising strategy to modify disease progression at its root.”.

“阻断心脏FGF23/FGFR4过度活跃有很强的潜力成为数百万慢性肾病患者面临心脏重构和心力衰竭进展风险的非常有前景的治疗选择，”EvlaBio首席运营官兼联合创始人托马斯·基尔迈尔表示。“心力衰竭是这一患者群体发病和死亡的主要原因，而我们的治疗方法提供了一种从根源上改变疾病进展的有希望的策略。”

The seed round was led by

种子轮融资由

Kurma Partners

库尔马合伙人

,

，

AdBio Partners

阿德生物伙伴

,

，

Boehringer Ingelheim Venture Fund

勃林格殷格翰风险基金

,

，

NRW.Venture

北莱茵-威斯特法伦州创业

(NRW.BANK) and

（NRW.BANK）和

HTGF

高特福

, and will enable EvlaBio to complete preclinical development and progress towards IND-enabling studies.

，并将使EvlaBio能够完成临床前开发并推进到支持新药临床试验（IND）的研究。

(Press release / SK)

（新闻稿 / SK）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送